IMMUNIC, INC. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Immunic, Inc. (IMUX) on July 7, 2022, reporting events occurring on July 5, 2022. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes.
Material Changes
The filing discloses significant changes to the Board of Directors effective July 5, 2022:
- Appointment: Monika Maria Törnsén was appointed as a Class III director. Her term extends until the 2023 annual meeting of stockholders.
- Resignation: Jan Van den Bossche resigned from the Board. The resignation was accepted effective July 5, 2022, and was not due to any disagreement with the Company regarding operations, policies, or practices.
Compensatory Arrangements and Outlook
In connection with her appointment, Ms. Törnsén received the following compensatory arrangements:
- Equity Grant: An option to purchase 30,000 shares of common stock.
- Vesting Schedule: 10,000 shares vest monthly over one year; 20,000 shares vest monthly over three years.
- Exercise Price: Set at the closing price of the Company's common stock on the grant date.
- Indemnification: Ms. Törnsén entered into the Company's standard director indemnification agreement.
The filing contains no forward-looking guidance, risk factors, or discussion of unusual items beyond the standard disclosure of the director transition.
Investor Verification Checklist
- Verify the exact grant date and exercise price of the 30,000 share option granted to Ms. Törnsén.
- Confirm the total number of outstanding shares and the impact of this new option grant on potential dilution.
- Review the Company's proxy statement or subsequent filings to confirm the composition of the Board following the resignation of Mr. Van den Bossche.
- Check for any related party transactions involving the new director, though the filing states none exist.